as 12-20-2024 4:00pm EST
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
Founded: | 2012 | Country: | United States |
Employees: | N/A | City: | THOUSAND OAKS |
Market Cap: | 65.1M | IPO Year: | 2014 |
Target Price: | $26.50 | AVG Volume (30 days): | 77.5K |
Analyst Decision: | Buy | Number of Analysts: | 6 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -22.60 | EPS Growth: | N/A |
52 Week Low/High: | $6.50 - $39.50 | Next Earning Date: | 11-12-2024 |
Revenue: | $100,439,000 | Revenue Growth: | 2111.34% |
Revenue Growth (this year): | 1346.63% | Revenue Growth (next year): | -6.95% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Henrich Jill | ATRA | EVP, Chief Regulatory Officer | Nov 18 '24 | Sell | $11.20 | 1,000 | $11,198.00 | 19,378 | |
Nguyen AnhCo | ATRA | President and CEO | Nov 18 '24 | Sell | $11.20 | 1,664 | $18,633.47 | 77,454 | |
Hyllengren Eric J | ATRA | EVP, CFO and COO | Nov 18 '24 | Sell | $11.20 | 1,364 | $15,274.07 | 23,392 |
ATRA Breaking Stock News: Dive into ATRA Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
GlobeNewswire
19 days ago
Business Wire
25 days ago
Simply Wall St.
a month ago
Business Wire
a month ago
Zacks
a month ago
Associated Press Finance
a month ago
Business Wire
a month ago
The information presented on this page, "ATRA Atara Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.